NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Biotechnology · USD

Faeth Therapeutics, Inc. (FTH) Stock Analysis

Faeth Therapeutics, Inc. (FTH) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

FTH

$20.10

−$0.47 (−2.28%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FTH with… →

FTH Key Statistics

As of Oct 22, 2026
Trading
Open
$20.40
Previous Close
$20.57
Day's Range
20.00–21.65
52-Week Range
7.45–42.14
Volume
314.49K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.29
Valuation
Market Cap
$519.39M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−60.86
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$21.09M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
25.84M
1-Year Return
+85.94%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
353.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 22, 2026, FTH closed at $20.10, +85.94% over 1 year.

Faeth Therapeutics, Inc. (FTH) has a market capitalization of $519.39M.

In fiscal 2025, FTH reported revenue of $0.00.

FTH Stock Return by Calendar Year

Faeth Therapeutics, Inc. (FTH) return since Feb 2021: what $10,000 became

1 year
$10,000 $18,594
+85.94%
5 years
$10,000 $1,426
−85.74%
Since Feb 2021
$10,000 $532
−94.68%

If you had invested $10,000 in Faeth Therapeutics, Inc. (FTH) at the close on February 4, 2021, the earliest close on record here, it would have been worth $532 at the close on October 22, 2026: −94.68% in total, −40.18% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+88.38%
2025+8.88%
2024−29.19%
2023−53.56%
2022−74.31%
2021 (partial year)−69.31%

As of October 22, 2026.

FTH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$21.09M—
2024$0.00−$30.16M—
2023$0.00−$34.10M—
2022$0.00−$48.59M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$22.29M−$21.09M—
2024$0.00—−$31.66M−$30.16M—
2023$0.00—−$37.06M−$34.10M—
2022$0.00—−$50.19M−$48.59M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Faeth Therapeutics, Inc. (FTH) is capitalised at $519.39M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 29 employees.

FTH last closed at $20.10 on October 22, 2026. That is −$0.47 (−2.28%) against the previous close. Over the past 52 weeks the price has ranged from $7.45 to $42.14. The latest close sits 169.8% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $21.09M. Earnings per share on a trailing basis come to −60.86.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −0.29. Annualized volatility over the trailing 5 years is 134.16%. Over the trailing twelve months the total return is +85.94%. Measured over 5 years, that is −32.27% a year compounded.

Growth & Income

The record shows no dividend for FTH.

The strongest complete calendar year on file is 2025 at +8.88%; the weakest is 2022 at −74.31%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the total return is +88.38%.

Peer Comparison

Faeth Therapeutics, Inc. (FTH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Faeth Therapeutics, Inc. FTH $519.39M —
Vertex Pharmaceuticals Incorporated VRTX $135.64B 31.0
Regeneron Pharmaceuticals, Inc. REGN $84.33B 20.3
Moderna, Inc. MRNA $80.90B —

The Biotechnology industry average P/E ratio is 16.6x. Faeth Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$135.64B

 REGN

Regeneron Pharmaceuticals, Inc.

$84.33B

 MRNA

Moderna, Inc.

$80.90B

 ARGX

argenx SE

$55.07B

 ONC

BeOne Medicines AG

$43.49B

 RVMD

Revolution Medicines, Inc.

$40.23B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

Visit website →